萬泰生物(603392.SH):與養生堂達成關於溶瘤病毒技術轉讓及服務協議的補充協議
格隆匯 12 月 30日丨萬泰生物(603392.SH)公佈,2020年受疫情影響,公司未能按照《轉讓協議》約定在2020年12月31日前完成溶瘤病毒一期和二期臨牀樣品的生產、檢定和放行服務。截止公吿日,公司已為養生堂完成溶瘤病毒的I期臨牀試驗用藥物,還未開展II期臨牀試驗用藥物的生產工作。鑑於此,經公司與養生堂協商後達成《關於<溶瘤病毒技術轉讓及服務協議>的補充協議》。
自補充協議簽署之日,公司繼續履行原《轉讓協議》的約定,為養生堂及其關聯方提供溶瘤病毒重組人PD1抗體單純皰疹病毒一、二期臨牀試驗用藥物的生產、檢定和放行服務。技術服務主要工作內容參照原《轉讓協議》附件二中待完成部分。
服務期限:補充協議簽訂後至2021年12月31日期間。如屆時因全球新冠肺炎疫情影響或其他因素導致公司仍未能按時履行原《轉讓協議》及補充協議項下尚未履行的合同義務的,雙方另行協商延長服務期限。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.